Your browser doesn't support javascript.
loading
Acute and long-term management of severe bronchiectasis with high flow nasal therapy: A case report.
Impellizzeri, Pietro; Nolasco, Santi; Campisi, Raffaele; Cipolla, Antonino; Borgese, Alba; Alia, Stefano; Crimi, Nunzio; Crimi, Claudia.
Affiliation
  • Impellizzeri P; Department of Clinical and Experimental Medicine, University of Catania. pietroimpellizeri2018@gmail.com.
  • Nolasco S; Department of Clinical and Experimental Medicine, University of Catania. nolascos@hotmail.it.
  • Campisi R; Respiratory Medicine Unit, Policlinico "G. Rodolico - San Marco" University Hospital, Catania. raffaelemd@gmail.com.
  • Cipolla A; Department of Clinical and Experimental Medicine, University of Catania. ninocipolla95@tiscali.it.
  • Borgese A; Department of Clinical and Experimental Medicine, University of Catania. alba.borgese@libero.it.
  • Alia S; Respiratory Medicine Unit, Policlinico "G. Rodolico - San Marco" University Hospital, Catania, Italy. stefanoalia@libero.it.
  • Crimi N; Department of Clinical and Experimental Medicine, University of Catania. crimi@unict.it.
  • Crimi C; Respiratory Medicine Unit, Policlinico "G. Rodolico - San Marco" University Hospital, Catania. dott.claudiacrimi@gmail.com.
Monaldi Arch Chest Dis ; 93(2)2022 Aug 04.
Article in En | MEDLINE | ID: mdl-35929643
Bronchiectasis (BE) is a long-term, chronic lung condition featured by widened and scarred airways. These can alter the physiological mucociliary clearance, making it difficult to clear mucus and microorganisms, leading to frequent exacerbations. High flow nasal therapy (HFNT) is a noninvasive respiratory support that delivers heated and humidified gas eventually enriched with oxygen, through a nasal cannula.  Humidification is crucial for adequate airways mucociliary clearance, improving ciliary function and consequently reducing airways inflammation and recurrent infections. HFNT has been mostly used in patients with acute hypoxemic respiratory failure and in selected patients with chronic respiratory failure due to COPD. Still, evidence about its use in acute and long-term home setting in patients with clinically relevant BE are lacking. We report a case of severe widespread BE, already on top medical therapy and pulmonary rehabilitation, still suffering from difficult mucus expectoration and recurrent exacerbations, who has been additionally treated with HFNT, both in hospital and domiciliary, reporting significant improvements on relevant clinical and patient-centered outcomes. Thus, HFNT may confer additional benefits as an add-on treatment of patients with severe BE and respiratory failure.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Insufficiency / Acidosis, Respiratory / Bronchiectasis Limits: Humans Language: En Journal: Monaldi Arch Chest Dis Year: 2022 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Respiratory Insufficiency / Acidosis, Respiratory / Bronchiectasis Limits: Humans Language: En Journal: Monaldi Arch Chest Dis Year: 2022 Type: Article